A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group

被引：0
|
作者：
Swaby, R. F.
Wang, M.
Sparano, J. A.
Bhalla, K.
Meropol, N. J.
Falkson, C., I
Pellegrino, C. M.
Klein, P.
Goldstein, L. J.
Sledge, Jr G. W.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Montefiore Hosp, Bronx, NY USA
[4] Med Coll Georgia, Augusta, GA 30912 USA
[5] Univ Alabama, Birmingham, AL USA
[6] St Vincents Comp Canc Ctr, New York, NY USA
[7] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：793S / 793S
页数：1
相关论文
共 11 条
  • [1] A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)
    Lori J. Goldstein
    Fengmin Zhao
    Molin Wang
    Ramona F. Swaby
    Joseph A. Sparano
    Neal J. Meropol
    Kapil N. Bhalla
    Christine M. Pellegrino
    R. Katherine Alpaugh
    Carla I. Falkson
    Paula Klein
    George W. Sledge
    Breast Cancer Research and Treatment, 2017, 165 : 375 - 382
  • [2] A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)
    Goldstein, Lori J.
    Zhao, Fengmin
    Wang, Molin
    Swaby, Ramona F.
    Sparano, Joseph A.
    Meropol, Neal J.
    Bhalla, Kapil N.
    Pellegrino, Christine M.
    Alpaugh, R. Katherine
    Falkson, Carla I.
    Klein, Paula
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (02) : 375 - 382
  • [3] A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
    Stacy Moulder
    Hailun Li
    Molin Wang
    William J. Gradishar
    Edith A. Perez
    Joseph A. Sparano
    Michael Pins
    Ximing Yang
    George W. Sledge
    Breast Cancer Research and Treatment, 2010, 119 : 663 - 671
  • [4] A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
    Moulder, Stacy
    Li, Hailun
    Wang, Molin
    Gradishar, William J.
    Perez, Edith A.
    Sparano, Joseph A.
    Pins, Michael
    Yang, Ximing
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (03) : 663 - 671
  • [5] A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)
    Tianhong Li
    Mengye Guo
    William J. Gradishar
    Joseph A. Sparano
    Edith A. Perez
    Molin Wang
    George W. Sledge
    Breast Cancer Research and Treatment, 2012, 134 : 345 - 352
  • [6] A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)
    Li, Tianhong
    Guo, Mengye
    Gradishar, William J.
    Sparano, Joseph A.
    Perez, Edith A.
    Wang, Molin
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 345 - 352
  • [7] Phase I/II Study of BKM120 in Combination with Trastuzumab in Patients with HER2 Overexpressing Metastatic Breast Cancer Resistant to Trastuzumab-Containing Therapy
    Saura, C.
    Bendell, J.
    Jerusalem, G.
    Grana-Suarez, B.
    Su, S.
    Ru, Q.
    De Buck, S.
    Devisme, C.
    Bosch, A.
    Urruticoechea, A.
    Beck, J. T.
    DiTomaso, E.
    Rouyrre, N.
    Sternberg, D. W.
    Massacesi, C.
    Hirawat, S.
    Dirix, L.
    Baselga, J.
    CANCER RESEARCH, 2011, 71
  • [8] Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial
    Saip, P.
    Eralp, Y.
    Sen, F.
    Karaca, H.
    Ozkan, M.
    Cetin, B.
    Benekli, M.
    Kucukoner, M.
    Isikdogan, A.
    Un, O.
    Basaran, G.
    Onur, H.
    BREAST, 2013, 22 (05): : 628 - 633
  • [9] A phase II trial of trastuzumab, weekly ixabepilone (BMS-247550) and carboplatin (TIC) in patients with HER2/neupositive (HER2+) metastatic breast cancer (MBC): a trial coordinated by the Eastern Cooperative Oncology Group (E2103).
    Moulder, S.
    Wang, M.
    Gradishar, W.
    Perez, E. A.
    Sporano, J.
    Pins, M.
    Sledge, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S270 - S271
  • [10] A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+MBC): A trial of the Eastern Cooperative Oncology Group (E1105)
    Arteaga, Carlos L.
    Mayer, Ingrid A.
    O'Neill, Anne M.
    Swaby, Ramona F.
    Alpaugh, R. Katherine
    Yang, Ximing J.
    Wagner, Lynne I.
    Meropol, Neal J.
    Saphner, Thomas James
    Jahanzeb, Mohammad
    Perez, Edith A.
    Lin, Nancy U.
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12